Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Rating of “Buy” from Brokerages

Quince Therapeutics, Inc. (NASDAQ:QNCX) has received an average recommendation of “Buy” from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $9.50.

QNCX has been the subject of several research reports. RODMAN&RENSHAW upgraded Quince Therapeutics to a “strong-buy” rating in a report on Tuesday, October 29th. Brookline Capital Management began coverage on shares of Quince Therapeutics in a report on Wednesday, December 18th. They set a “buy” rating and a $9.00 price objective on the stock. Rodman & Renshaw assumed coverage on Quince Therapeutics in a report on Tuesday, October 29th. They set a “buy” rating and a $11.00 price objective on the stock. EF Hutton Acquisition Co. I upgraded Quince Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 22nd. Finally, Maxim Group began coverage on Quince Therapeutics in a research note on Thursday, November 7th. They issued a “buy” rating and a $6.00 target price for the company.

Quince Therapeutics Price Performance

Shares of QNCX opened at $1.61 on Monday. Quince Therapeutics has a one year low of $0.51 and a one year high of $2.45. The stock’s fifty day moving average is $1.84 and its 200-day moving average is $1.25. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.53 and a current ratio of 9.53. The firm has a market capitalization of $70.84 million, a price-to-earnings ratio of -1.30 and a beta of 0.64.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Quince Therapeutics stock. Scharf Investments LLC acquired a new stake in shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 91,061 shares of the company’s stock, valued at approximately $170,000. Scharf Investments LLC owned about 0.21% of Quince Therapeutics at the end of the most recent quarter. Institutional investors own 30.75% of the company’s stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.